CA: A Cancer Journal for Clinicians · Nov 2026
American Cancer Society guideline for the early detection of prostate cancer, 2026
Richard M. Hoffmanh-index 46, Andrew M. D. Wolf, Ruth D. Etzioni, Kevin C. Oeffinger, Sana Raoof, Louise C. Walter, Charnita Zeigler‐Johnson, Timothy R. Church, Christopher K. Jones, Artie L. Shelton, Elena B. Elkin, Carmen E. Guerra, Rebecca B. Perkins, Ya‐Chen Tina Shihh-index 50, Steven J. Skates, Roman Gulati, Hormuzd A. Katki, Tyler B. Kratzer, Deana Manassaram‐Baptiste, William L. Dahut, Robert A. Smithh-index 23
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- Crossref3
- Europe PMC1
- OpenCitations0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract The goal of prostate cancer screening is to reduce morbidity and mortality through the early detection of clinically significant disease. Accumulating evidence shows that prostate‐specific antigen (PSA)‐based screening significantly reduces prostate cancer mortality and advanced‐stage diagnosis, and approaches to reduce harms associated with screening are increasingly being used. The ACS conducted a systematic review and commissioned a modeling study to evaluate PSA‐based screening strategies, and concluded that the benefits of screening outweigh the harms. Before initiating screening, clinicians should ensure that patients are informed about the benefits, limitations, and harms of screening; the potential follow‐up evaluations of elevated PSA levels; and the expectation that low‐risk cancers will initially be managed with active surveillance. The ACS recommends biennial screening from ages 50‐69 years for average‐risk men (i.e., non‐Black men without a family history of prostate cancer). Annual screening from ages 45‐69 years is recommended for Black men. Annual screening from ages 45–69 years is recommended for non‐Black men with a strong family history (i.e., multiple first‐degree relatives diagnosed with prostate cancer at any age or one diagnosed before age 65 years). Biennial screening from ages 45‐69 years is recommended for non‐Black men with a single first‐degree relative diagnosed at age 65 years or older. For men ages 70–74 years, the balance of benefits and harms is uncertain, and individualized decision making is recommended. The ACS recommends further evaluating men ages 45–69 years with PSA levels ≥3.0 ng/mL and men ages 70–74 years with PSA levels ≥6.5 ng/mL. Most men who have elevated PSA levels confirmed on repeat testing should be offered magnetic resonance imaging and/or a validated biomarker test to guide biopsy decisions. Screening is not recommended for men with a life expectancy <10 years and should be discontinued at age 75 years.
What the data shows
- Crossref counts 3 citations, the most of the databases. The others count 0 to 1.
- Ya‐Chen Tina Shih has the highest h-index among the authors (50).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (83)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 63 more references
A free account opens the rest of the citing papers and references on every paper’s page.